Cell Proliferation News and Research

RSS

Scientists identify specific enzyme essential for brain development

Scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna have identified a specific enzyme, histone deacetylase 2 (HDAC2), as essential for brain development. The findings published in Development are important to advance the development of new drugs to treat neurological diseases.

22 Jan 2014

Splicing factor SRSF6 promotes hyperplasia of sensitized skin

Normally, tissue injury triggers a mechanism in cells that tries to repair damaged tissue and restore the skin to a normal, or homeostatic state. Errors in this process can give rise to various problems, such as chronic inflammation, which is a known cause of certain cancers.

21 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Erythropoietin may promote cancer cell proliferation and survival

In recent years, non-hematopoietic effects of erythropoietin (EPO), via its binding to the EPO receptor in non-hematopoietic tissues, including cancerous tissues, has been reported by many different laboratories worldwide.

7 Jan 2014

Hotspots of fuel consumption in adult brain also show key characteristics of developing brain

Although brain growth slows as individuals age, some regions of the brain continue to develop for longer than others, creating new connections and remodeling existing circuitry.

7 Jan 2014

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program, earning a $25 million payment under the company's collaboration with Celgene Corporation.

7 Jan 2014

Manipulating epigenetic mechanism may promote cell death in pediatric brain cancer

Researchers at the Federal University of Rio Grande do Sul, the university hospital (Hospital de Cl-nicas de Porto Alegre, HCPA) and the Children's Cancer Institute (Instituto do C-ncer Infantil do Rio Grande do Sul, ICI-RS) in Porto Alegre, Brazil, have shown that manipulating an epigenetic mechanism, which regulates gene expression, may promote cell death and favor maturation towards less malignant-prone phenotypes in pediatric brain cancer cell lines.

22 Dec 2013

Study finds milk serves as protective carrier of bioactive molecules

Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

20 Dec 2013

New surface treatment processes for orthopaedic and dental implants to reduce risk of infection

Researchers at Aalto University have developed a method of selection of new surface treatment processes for orthopaedic and dental implants to reduce the risk of infection.

19 Dec 2013

Two existing drugs show promise as potential treatments for cervical cancer

Two existing drugs - one the active ingredient in an anti-fungal medication and the other now used to control iron levels in the blood - both show promise as potential treatments for cervical cancer, according to newly published research by scientists at Rutgers New Jersey Medical School.

17 Dec 2013

Dysfunction of retinoblastoma enables inhibitory protein to promote pancreatic cancer growth

Indiana University cancer researchers have discovered that a protein that normally suppresses tumors actually promotes the growth and spread of pancreatic cancer.

16 Dec 2013

Researchers study zebrafish embryo skin to find link between low calcium and colon cancer

A tiny, transparent fish embryo and a string of surprises led scientists to a deeper understanding of the perplexing link between low calcium and colon cancer.

14 Dec 2013

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest, but prevent the proliferation of cells as they have a reduced capacity to synthesize proteins.

12 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Equations help explain key parameters of stents that combat artherosclerosis

Coronary heart disease accounts for 18% of deaths in the United States every year. The disease results from a blockage of one or more arteries that supply blood to the heart muscle.

9 Dec 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

New form of gene therapy shows promising outcomes for "bubble boy" disease

Researchers reported promising outcomes data for the first group of boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a fatal genetic immunodeficiency also known as "bubble boy" disease, who were treated as part of an international clinical study of a new form of gene therapy. The mechanism used to deliver the gene therapy is designed to prevent the serious complication of leukemia that arose a decade ago in a similar trial in Europe, when one-quarter of boys treated developed the blood cancer.

9 Dec 2013

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr. Sachdev Sidhu at the University of Toronto and the laboratory of Dr. Joseph Schlessinger of Yale University.

6 Dec 2013

Study uncovers novel mechanism by which glioblastoma evades targeted therapies

A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.

6 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

Cell Proliferation News and Research

Scientists identify specific enzyme essential for brain development

Splicing factor SRSF6 promotes hyperplasia of sensitized skin

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Erythropoietin may promote cancer cell proliferation and survival

Hotspots of fuel consumption in adult brain also show key characteristics of developing brain

Epizyme achieves POC milestone in EPZ-5676 DOT1L inhibitor clinical program

Manipulating epigenetic mechanism may promote cell death in pediatric brain cancer

Study finds milk serves as protective carrier of bioactive molecules

New surface treatment processes for orthopaedic and dental implants to reduce risk of infection

Two existing drugs show promise as potential treatments for cervical cancer

Dysfunction of retinoblastoma enables inhibitory protein to promote pancreatic cancer growth

Researchers study zebrafish embryo skin to find link between low calcium and colon cancer

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Equations help explain key parameters of stents that combat artherosclerosis

Novel multi-kinase inhibitor shows early promise in NSCLC

New form of gene therapy shows promising outcomes for "bubble boy" disease

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Study uncovers novel mechanism by which glioblastoma evades targeted therapies

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News